Cargando…
Neoadjuvant Therapy for Resectable Pancreatic Cancer: An Evolving Paradigm Shift
Non-metastatic pancreatic adenocarcinoma (PDAC) is associated with a high rate of recurrence and lethality. In addition, less than half of all patients are able to complete systemic therapy after curative-intent pancreatectomy. With its well-known potential benefits, this report highlights the curre...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811513/ https://www.ncbi.nlm.nih.gov/pubmed/31681614 http://dx.doi.org/10.3389/fonc.2019.01085 |